Moving forward, the Alpl−/− severe HPP murine model used in this work that is characterized by early muscle weakness is a good candidate to better understand muscular consequences of HPP in humans and muscle response to asfotase alpha therapy. This evidence concerns the gene ALPL and hypophosphatasia.